- Trials with a EudraCT protocol (68)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
68 result(s) found for: Acute Schizophrenia AND Acute Disease.
Displaying page 3 of 4.
EudraCT Number: 2012-003806-28 | Sponsor Protocol Number: 31-12-297 | Start Date*: 2013-03-25 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, | |||||||||||||
Full Title: A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001665-12 | Sponsor Protocol Number: KAR-012 | Start Date*: 2023-01-05 | |||||||||||
Sponsor Name:Karuna Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia. | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023369-23 | Sponsor Protocol Number: 40411813SCH2001INT-1/GER-2 | Start Date*: 2011-04-05 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: FIRST-IN-PATIENT STUDY TO ASSESS THE SAFETY AND TOLERABILITY AND TO EXPLORE THE POTENTIAL THERAPEUTIC EFFICACY OF A NOVEL GLUTAMATE MODULATOR AS MONOTHERAPY AND AS ADD-ON THERAPY IN PATIENTS WITH S... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) AT (Completed) ES (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001097-90 | Sponsor Protocol Number: 11915A | Start Date*: 2008-09-23 | |||||||||||
Sponsor Name:H. Lundbeck A/S | |||||||||||||
Full Title: A one-year multinational, multi-centre, randomised, double-blind, parallel-group, fixed-dose, bifeprunox study combining a 12 week placebo-controlled, quetiapine-referenced phase with a 12-month qu... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017853-36 | Sponsor Protocol Number: H8Y-MC-HBBO | Start Date*: 2010-09-07 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003760-11 | Sponsor Protocol Number: 1346-0011 | Start Date*: 2021-06-08 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin (BI 425809) once daily over 26 week treatment period in patients with ... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) PL (Completed) NO (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005134-21 | Sponsor Protocol Number: HP-3070-GL-04 | Start Date*: 2016-07-01 | |||||||||||
Sponsor Name:Noven Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012031-15 | Sponsor Protocol Number: 01KG0910 | Start Date*: 2009-11-19 | |||||||||||||||||||||
Sponsor Name:Technische Universitaet Muenchen, vertreten durch das Klinikum rechts der Isar | |||||||||||||||||||||||
Full Title: The switch study - efficacy of early antipsychotic switch versus maintenance in patients with schizophrenia poorly responding to two weeks of antipsychotic treatment | |||||||||||||||||||||||
Medical condition: Patients with a diagnosis of schizophrenia , schizophreniform disorder or schizoaffective disorder according to DSM-IV TR criteria; experiencing an acute episode of their illness | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) RO (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-004783-31 | Sponsor Protocol Number: D3690C00007 | Start Date*: 2007-02-02 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Dos... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000497-11 | Sponsor Protocol Number: ALK3831-A307 | Start Date*: 2017-07-13 | |||||||||||||||||||||
Sponsor Name:Alkermes Inc | |||||||||||||||||||||||
Full Title: A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | |||||||||||||||||||||||
Medical condition: Schizophrenia, schizophreniform disorder or bipolar I disorder | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: AT (Completed) DE (Completed) ES (Ongoing) IT (Completed) RO (Ongoing) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001514-15 | Sponsor Protocol Number: EARLY_KUM_PSY | Start Date*: 2018-12-10 | |||||||||||
Sponsor Name:Bezirkskliniken Schwaben | |||||||||||||
Full Title: Effects of early clozapine treatment on remission rates in acute schizophrenia (EARLY) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001211-39 | Sponsor Protocol Number: ALK3831-401 | Start Date*: 2015-01-27 |
Sponsor Name:Alkermes, Inc. | ||
Full Title: A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder | ||
Medical condition: Schizophrenia with alcohol use disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BG (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-003342-15 | Sponsor Protocol Number: F1D-MC-HGMT | Start Date*: 2007-12-05 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of Schizophrenia | ||
Medical condition: Schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) FR (Completed) GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001151-16 | Sponsor Protocol Number: CVL-231-2003 | Start Date*: 2022-10-25 | ||||||||||||||||
Sponsor Name:Cerevel Therapeutics, LLC | ||||||||||||||||||
Full Title: A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 in Adult Participants With Schizophrenia | ||||||||||||||||||
Medical condition: Patients with schizophrenia who are experiencing an acute exacerbation of psychosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Trial now transitioned) BG (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002304-41 | Sponsor Protocol Number: RIS-SCH-4045 | Start Date*: 2005-09-23 |
Sponsor Name:Janssen-Cilag EMEA Medical Affairs | ||
Full Title: Early versus late initiation of treatment with Risperdal Consta in subjects with schizophrenia or schizoaffective disorder after an acute episode | ||
Medical condition: Schizophrenia or schizoaffective disorder. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) DK (Completed) FI (Completed) GB (Completed) SI (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018911-13 | Sponsor Protocol Number: 31-09-267 | Start Date*: 2011-06-14 | ||||||||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | ||||||||||||||||||
Full Title: A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients with Schizophrenia... | ||||||||||||||||||
Medical condition: Schizophrenia in Adolescent Patients or Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-014811-11 | Sponsor Protocol Number: R076477PSZ3003 | Start Date*: 2010-01-25 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Estudio multicéntrico, aleatorizado, doble ciego, controlado, de dosis flexibles y grupos paralelos para evaluar la eficacia y seguridad de paliperidona de liberación prolongada en el tratamiento d... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) CZ (Completed) SK (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005734-20 | Sponsor Protocol Number: R076477-SCA-3002 | Start Date*: 2008-04-24 | |||||||||||
Sponsor Name:Janssen L.P. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Flexible Dose Paliperidone ER in the Treatment of Subjects with Schizoaffective Disorder | |||||||||||||
Medical condition: Schizoaffective disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015629-35 | Sponsor Protocol Number: R076477SCH3038 | Start Date*: 2009-11-05 |
Sponsor Name:Janssen-Cilag NV/SA | ||
Full Title: Open-label, single arm, interventional study to explore the efficacy and safety of paliperidone ER in the management of patients with acute agitation and/or aggression | ||
Medical condition: Subject presenting with acute agitation and/or agression in the context of psychosis, suspected schizophrenia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-007083-22 | Sponsor Protocol Number: 37822681SCH2002, INT-1, 10 FEB 2009 | Start Date*: 2008-10-01 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of JNJ-37822681 Administered Twice Daily in Subjects With Schiz... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
